1. Macmillan AK, Merrie AE, Marshall RJ, Parry BR. The prevalence of fecal incontinence in community-dwelling adults: a systematic review of the literature. Dis Colon Rectum 2004;47:1341–9.
2. Shafik A. Polytetrafluoroethylene injection for the treatment of partial fecal incontinence. Int Surg 1993;78:159–61.
3. Kumar D, Benson MJ, Bland JE. Glutaraldehyde cross- linked collagen in the treatment of faecal incontinence. Br J Surg 1998;85:978–9.
4. Shafik A. Perianal injection of autologous fat for treatment of sphincteric incontinence. Dis Colon Rectum 1995;38:583–7.
5. Malouf AJ, Vaizey CJ, Norton CS, Kamm MA. Internal anal sphincter augmentation for fecal incontinence using injectable silicone biomaterial. Dis Colon Rectum 2001; 44:595–600.
6. Chan MK, Tjandra JJ. Injectable silicone biomaterial (PTQ) to treat fecal incontinence after hemorrhoidectomy. Dis Colon Rectum 2006;49:433–9.
7. Tjandra JJ, Lim JF, Hiscock R, Rajendra P. Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective. Dis Colon Rectum 2004;47:2138–46.
8. Kenefick NJ, Vaizey CJ, Malouf AJ, Norton CS, Marshall M, Kamm MA. Injectable silicone biomaterial for faecal incontinence due to internal anal sphincter dysfunction. Gut 2002;51:225–8.
9. Davis K, Kumar D, Poloniecki J. Preliminary evaluation of an injectable anal sphincter bulking agent (Durasphere) in the management of faecal incontinence. Aliment Pharmacol Ther 2003;18:237–43.
10. Pannek J, Brands FH, Senge T. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol 2001;166:1350–3.
11. Emans PJ, Saralidze K, Knetsch ML, Gijbels MJ, Kuijer R, Koole LH. Development of new injectable bulking agents: biocompatibility of radiopaque polymeric microspheres studied in a mouse model. J Biomed Mater Res A 2005;73:430–6.
12. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmet- ric self-renewal and commitment of satellite stem cells in muscle. Cell 2007;129:999–1010.
13. Qu-Petersen Z, Deasy B, Jankowski R, et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 2002;157:851–64.
14. Lee JY, Paik SY, Yuk SH, Lee JH, Ghil SH, Lee SS. Long term effects of muscle-derived stem cells on leak point pressure and closing pressure in rats with transected pudendal nerves. Mol Cells 2004;18:309–13.
15. Cannon TW, Lee JY, Somogyi G, et al. Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology 2003;62: 958–63.
16. Yiou R, Yoo JJ, Atala A. Restoration of functional motor units in a rat model of sphincter injury by muscle precursor cell autografts. Transplantation 2003;76:1053– 60.
17. Kwon D, Kim Y, Pruchnic R, et al. Periurethral cellular injection: comparison of muscle-derived progenitor cells
and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. Urology 2006;68:449–54.
18. Lee JY, Cannon TW, Pruchnic R, Fraser MO, Huard J, Chancellor MB. The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:31–7.
19. Yiou R, Dreyfus P, Chopin DK, Abbou CC, Lefaucheur JP. Muscle precursor cell autografting in a murine model of urethral sphincter injury. BJU Int 2002;89:298–302.
20. Chermansky CJ, Tarin T, Kwon DD, et al. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology 2004;63:780–5.
21. Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet 2007;369:2179–86.
22. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis 2003;18:451–4.
23. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005;48:1416–23.
24. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994;125:1275–87.
25. Huard J, Yokoyama T, Pruchnic R, et al. Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther 2002;9:1617–26.
26. Gulbins H, Pritisanac A, Anderson I, et al. Myoblasts for survive 16 weeks after intracardiac transfer and start differentiation. Thorac Cardiovasc Surg 2003;51:295–300.
27. Hwang JH, Yuk SH, Lee JH, et al. Isolation of muscle derived stem cells from rat and its smooth muscle differentiation. Mol Cells 2004;17:57–61.
28. Qu Z, Balkir L, van Deutekom JC, Robbins PD, Pruchnic R, Huard J. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 1998;142:1257–67.
29. Beauchamp JR, Heslop L, Yu DS, et al. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J Cell Biol 2000;151:1221–34.
30. Yokoyama T, Huard J, Chancellor MB. Myoblast therapy for stress urinary incontinence and bladder dysfunction. World J Urol 2000;18:56–61.
31. Hagège AA, Carrion C, Menasché P, et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2003;361:491–2.
32. Alameddine HS, Louboutin JP, Dehaupas M, Sebille A, Fardeau M. Functional recovery induced by satellite cell grafts in irreversibly injured muscles. Cell Transplant 1994;3:3–14.
33. Guettier-Sigrist S, Coupin G, Warter JM, Poindron P. Cell types required to efficiently innervate human muscle cells in vitro. Exp Cell Res 2000;259:204–12.